Danaher Co. (NYSE:DHR) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. reduced its holdings in Danaher Co. (NYSE:DHR) by 0.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,931,708 shares of the conglomerate’s stock after selling 98 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Danaher were worth $1,093,093,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Pacer Advisors Inc. lifted its stake in shares of Danaher by 0.4% during the third quarter. Pacer Advisors Inc. now owns 51,110 shares of the conglomerate’s stock worth $14,210,000 after purchasing an additional 220 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares during the period. LPL Financial LLC increased its position in shares of Danaher by 7.4% during the third quarter. LPL Financial LLC now owns 379,341 shares of the conglomerate’s stock worth $105,464,000 after acquiring an additional 26,124 shares during the last quarter. German American Bancorp Inc. increased its position in shares of Danaher by 5.8% in the 3rd quarter. German American Bancorp Inc. now owns 18,584 shares of the conglomerate’s stock worth $5,167,000 after purchasing an additional 1,022 shares during the last quarter. Finally, Citizens Financial Group Inc. RI lifted its position in shares of Danaher by 17.3% during the third quarter. Citizens Financial Group Inc. RI now owns 16,940 shares of the conglomerate’s stock worth $4,713,000 after purchasing an additional 2,499 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 0.4 %

Danaher stock opened at $232.25 on Thursday. Danaher Co. has a twelve month low of $215.68 and a twelve month high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a market cap of $167.75 billion, a PE ratio of 44.48, a P/E/G ratio of 4.25 and a beta of 0.85. The firm’s 50 day moving average price is $259.67 and its two-hundred day moving average price is $260.13.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the firm earned $2.02 earnings per share. The business’s quarterly revenue was up 3.1% compared to the same quarter last year. On average, research analysts predict that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on DHR. Raymond James reduced their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. UBS Group dropped their price objective on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. The Goldman Sachs Group raised their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Stephens reiterated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Monday. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.